| Literature DB >> 33211678 |
Thomas N Denny, Laura Andrews, Mattia Bonsignori, Kyle Cavanaugh, Michael B Datto, Anastasia Deckard, C Todd DeMarco, Nicole DeNaeyer, Carol A Epling, Thaddeus Gurley, Steven B Haase, Chloe Hallberg, John Harer, Charles L Kneifel, Mark J Lee, Raul Louzao, M Anthony Moody, Zack Moore, Christopher R Polage, Jamie Puglin, P Hunter Spotts, John A Vaughn, Cameron R Wolfe.
Abstract
On university campuses and in similar congregate environments, surveillance testing of asymptomatic persons is a critical strategy (1,2) for preventing transmission of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19). All students at Duke University, a private research university in Durham, North Carolina, signed the Duke Compact (3), agreeing to observe mandatory masking, social distancing, and participation in entry and surveillance testing. The university implemented a five-to-one pooled testing program for SARS-CoV-2 using a quantitative, in-house, laboratory-developed, real-time reverse transcription-polymerase chain reaction (RT-PCR) test (4,5). Pooling of specimens to enable large-scale testing while minimizing use of reagents was pioneered during the human immunodeficiency virus pandemic (6). A similar methodology was adapted for Duke University's asymptomatic testing program. The baseline SARS-CoV-2 testing plan was to distribute tests geospatially and temporally across on- and off-campus student populations. By September 20, 2020, asymptomatic testing was scaled up to testing targets, which include testing for residential undergraduates twice weekly, off-campus undergraduates one to two times per week, and graduate students approximately once weekly. In addition, in response to newly identified positive test results, testing was focused in locations or within cohorts where data suggested an increased risk for transmission. Scale-up over 4 weeks entailed redeploying staff members to prepare 15 campus testing sites for specimen collection, developing information management tools, and repurposing laboratory automation to establish an asymptomatic surveillance system. During August 2-October 11, 68,913 specimens from 10,265 graduate and undergraduate students were tested. Eighty-four specimens were positive for SARS-CoV-2, and 51% were among persons with no symptoms. Testing as a result of contact tracing identified 27.4% of infections. A combination of risk-reduction strategies and frequent surveillance testing likely contributed to a prolonged period of low transmission on campus. These findings highlight the importance of combined testing and contact tracing strategies beyond symptomatic testing, in association with other preventive measures. Pooled testing balances resource availability with supply-chain disruptions, high throughput with high sensitivity, and rapid turnaround with an acceptable workload.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33211678 PMCID: PMC7676642 DOI: 10.15585/mmwr.mm6946e1
Source DB: PubMed Journal: MMWR Morb Mortal Wkly Rep ISSN: 0149-2195 Impact factor: 17.586
Validation data* for the SARS-CoV-2 quantitative viral load assay indicating 100% target detection at 62 copies/mL and 74% at 15 copies/mL — Duke University, Durham, North Carolina, August–October 2020
| Sample ID† | Target viral load (RNA copies/mL) | % Detection (95% CI) | |
|---|---|---|---|
| Both replicates detected | Single replicate detected | ||
| Validation panel A | 5,000,000 | 100 (94.9–NE) | 100 (94.9–NE) |
| Validation panel B | 500,000 | 100 (94.9–NE) | 100 (94.9–NE) |
| Validation panel C | 50,000 | 100 (94.9–NE) | 100 (94.9–NE) |
| Validation panel D | 5,000 | 100 (94.9–NE) | 100 (94.9–NE) |
| Validation panel E | 500 | 100 (94.9–NE) | 100 (94.9–NE) |
| Validation panel F | 250 | 100 (94.9–NE) | 100 (94.9–NE) |
| Validation panel G | 125 | 99 (92.3–99.9) | 100 (94.9–NE) |
| Validation panel H | 62 | 83 (72.0–91.0) | 100 (94.9–NE) |
| Validation panel I | 31 | 56 (43.3–68.6) | 94 (86.0–98.4) |
| Validation panel J | 15 | 27 (17.2–39.1) | 74 (62.0–84.0) |
Abbreviations: CI = confidence interval; NE = not able to estimate.
* Validation panels were tested 70 times to determine limit of detection with 95% CIs.
† Genomic viral RNA was used to establish the validation panels.
Number of tests* positive for SARS-CoV-2 among students, by test category — Duke University, Durham, North Carolina, August 2–October 11, 2020
| Test category | No. of tests performed | No. of positive tests | No. (%) of persons† asymptomatic at testing |
|---|---|---|---|
| Entry testing | 8,873 | 17 | 9 (53) |
| Pooled testing§ | 59,476 | 29 | 29 (100) |
| Contact tracing¶ | 379 | 23 | 5 (22) |
| Symptom monitoring¶ | 185 | 15 | 0 (0) |
|
|
|
|
|
* Testing was performed on specimens from a total population of 10,265 undergraduate and graduate students residing on Duke University campus or in the surrounding Durham community.
† Who received positive test results.
§ Total number of positive pools = 158, which upon deconvolution yielded 29 individual positive specimens among students.
¶ Because numbers for total tests in contact tracing and symptom monitoring were encoded together, classifications of tests as resulting from contact tracing or symptom monitoring in this table represent an estimate.
FIGURECumulative number of nasal swab specimens processed for pooled SARS-CoV-2 real-time reverse transcription–polymerase chain reaction testing, August 18–October 11, 2020 (A) and viral load estimates for pooled (n = 158) and confirmatory specimens (n = 30), August–October 2020 (B)* — Duke University, Durham, North Carolina
Abbreviation: VL = viral load.
* In addition to data for students, plot includes data for one faculty member with a positive test result.